...
首页> 外文期刊>British Journal of Clinical Pharmacology >Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria.
【24h】

Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria.

机译:在患有严重恶性疟疾的非洲儿童中,单次肌肉注射蒿甲醚后,蒿甲醚和双氢青蒿素的群体药代动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To determine the population pharmacokinetics of artemether and dihydroartemisinin in African children with severe malaria and acidosis associated with respiratory distress following an intramuscular injection of artemether. METHODS: Following a single intramuscular (i.m.) injection of 3.2 mg kg-1 artemether, blood samples were withdrawn at various times over 24 h after the dose. Plasma was assayed for artemether and dihydroartemisinin by gas chromatography-mass spectrometry. The software program NONMEM was used to fit the concentration-time data and investigate the influence of a range of clinical characteristics (respiratory distress and metabolic acidosis, demographic features and disease) on the pharmacokinetics of artemether and dihydroartemisinin. RESULTS: A total of 100 children with a median age of 36.4 (range 5-108) months were recruited into the study and data from 90 of these children (30 with respiratory distress and 60 with no respiratory distress) were used in the population pharmacokinetic analysis. The best model to describe the disposition of artemether was a one-compartment model with first-order absorption and elimination. The population estimate of clearance (clearance/bioavailability, CL/F) was 14.3 l h-1 with 53% intersubject variability and that of the terminal half-life was 18.5 h. If it was assumed that artemisin displays 'flip-flop' kinetics, the elimination half-life was estimated to be 21 min and the corresponding volume of distribution was 8.44 l, with an intersubject variability of 104%. None of the covariates could be identified as having any influence on the disposition of artemether. The disposition of dihydroartemisinin was fitted separately using a one-compartment linear model in which the volume of distribution was fixed to the same value as that of artemether. Assuming that artemether is completely converted to dihydroartemisinin, the estimated value of CL/F for dihydroartemisinin was 93.5 l h-1, with an intersubject variability of 90.2%. The clearance of dihydroartemisinin was formation rate limited. CONCLUSIONS: Administration of a single 3.2 mg kg-1 i.m. dose of artemether to African children with severe malaria and acidosis is characterized by variable absorption kinetics, probably related to drug formulation characteristics rather than to pathophysiological factors. Use of i.m. artemether in such children needs to be reconsidered.
机译:目的:确定在肌肉内注射蒿甲醚后患有严重疟疾和酸中毒并伴呼吸窘迫的非洲儿童中蒿甲醚和双氢青蒿素的总体药代动力学。方法:在一次肌肉内(i.m.)注射3.2 mg kg-1蒿甲醚后,在给药后24小时内的不同时间抽血。通过气相色谱-质谱法测定血浆中的蒿甲醚和二氢青蒿素。软件程序NONMEM用于拟合浓度时间数据,并研究一系列临床特征(呼吸窘迫和代谢性酸中毒,人口统计学特征和疾病)对蒿甲醚和双氢青蒿素药代动力学的影响。结果:共招募了100名中位年龄为36.4岁(5-108个月)的儿童,并将其中90名儿童(30名呼吸窘迫和60名无呼吸窘迫)的数据用于人群药代动力学分析。描述蒿甲醚处置的最佳模型是具有一阶吸收和消除作用的单室模型。清除率的总体估计值(清除率/生物利用度,CL / F)为14.3 l h-1,受试者间差异为53%,最终半衰期为18.5 h。如果假设青蒿素显示“触发器”动力学,则消除半衰期估计为21分钟,相应的分配体积为8.44 l,受试者间变异性为104%。没有协变量可以被确定为对蒿甲醚的处置有任何影响。使用一室线性模型分别拟合二氢青蒿素的分布,在该模型中,分布体积固定为与蒿甲醚相同的值。假设蒿甲醚已完全转化为双氢青蒿素,则双氢青蒿素的CL / F估计值为93.5 l h-1,受试者间变异率为90.2%。二氢青蒿素的清除率受到限制。结论:单次3.2 mg kg-1 i.m.的给药。对患有严重疟疾和酸中毒的非洲儿童使用的蒿甲醚剂量具有变化的吸收动力学特征,这可能与药物配方特征有关,而不是与病理生理因素有关。使用i.m.需要重新考虑此类儿童中的蒿甲醚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号